SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mark Joachim)
 

Sökning: WFRF:(Mark Joachim) > Kinetic analysis of...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005211naa a2200469 4500
001oai:DiVA.org:uu-408918
003SwePub
008200417s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4089182 URI
0247 a https://doi.org/10.1186/s13550-020-0603-92 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Alhuseinalkhudhur, Aliu Uppsala universitet,Radiologi,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)alial794
2451 0a Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer
264 c 2020-03-23
264 1b SPRINGEROPEN,c 2020
338 a electronic2 rdacarrier
520 a Background: High expression of human epidermal growth factor receptor type 2 (HER2) represents an aggressive subtype of breast cancer. Anti-HER2 treatment requires a theragnostic approach wherein sufficiently high receptor expression in biopsy material is mandatory. Heterogeneity and discordance of HER2 expression between primary tumour and metastases, as well as within a lesion, present a complication for the treatment and require multiple biopsies. Molecular imaging using the HER2-targeting Affibody peptide ABY-025 radiolabelled with Ga-68-gallium for PET/CT is currently under investigation as a non-invasive tool for whole-body evaluation of metastatic HER2 expression. Initial studies demonstrated a high correlation between Ga-68-ABY-025 standardized uptake values (SUVs) and histopathology. However, detecting small liver lesions might be compromised by high background uptake. This study aimed to explore the applicability of kinetic modelling and parametric image analysis for absolute quantification of Ga-68-ABY-025 uptake and HER2-receptor expression and how that relates to static SUVs.Methods: Dynamic Ga-68-ABY-025 PET of the upper abdomen was performed 0-45 min post-injection in 16 patients with metastatic breast cancer. Five patients underwent two examinations to test reproducibility. Parametric images of tracer delivery (K-1) and irreversible binding (K-i) were created with an irreversible two-tissue compartment model and Patlak graphical analysis using an image-derived input function from the descending aorta. A volume of interest (VOI)-based analysis was performed to validate parametric images. SUVs were calculated from 2 h and 4 h post-injection static whole-body images and compared to K-i.Results: Characterization of HER2 expression in smaller liver metastases was improved using parametric images. K-i values from parametric images agreed very well with VOI-based gold standard (R-2 > 0.99, p < 0.001). SUVs of metastases at 2 h and 4 h post-injection were highly correlated with K-i values from both the two-tissue compartment model and Patlak method (R-2 = 0.87 and 0.95, both p < 0.001). Ga-68-ABY-025 PET yielded high test-retest reliability (relative repeatability coefficient for Patlak 30% and for the two-tissue compartment model 47%).Conclusion: Ga-68-ABY-025 binding in HER2-positive metastases was well characterized by irreversible two-tissue compartment model wherein K-i highly correlated with SUVs at 2 and 4 h. Dynamic scanning with parametric image formation can be used to evaluate metastatic HER2 expression accurately.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
653 a HER2 receptor
653 a Metastatic breast cancer
653 a Affibody
653 a Dynamic PET
653 a Kinetic modelling
7001 a Lubberink, Marku Uppsala universitet,Radiologi4 aut0 (Swepub:uu)marklubb
7001 a Lindman, Henriku Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)henrlind
7001 a Tolmachev, Vladimiru Uppsala universitet,Medicinsk strålningsvetenskap,Res Tomsk Polytech Univ, Res Ctr Oncotheranost, Res Sch Chem & Appl Biomed Sci, Tomsk, Russia4 aut0 (Swepub:uu)vladtolm
7001 a Frejd, Fredrik Y.u Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna, Sweden4 aut0 (Swepub:uu)freni195
7001 a Feldwisch, Joachimu Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna, Sweden4 aut0 (Swepub:uu)joafe691
7001 a Velikyan, Irina,d 1966-u Uppsala universitet,Radiologi4 aut0 (Swepub:uu)irinveli
7001 a Sörensen, Jensu Uppsala universitet,Radiologi4 aut0 (Swepub:uu)jenssore
7102 a Uppsala universitetb Radiologi4 org
7730 t EJNMMI Researchd : SPRINGEROPENg 10:1q 10:1x 2191-219X
8564 u https://doi.org/10.1186/s13550-020-0603-9y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1424370/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://ejnmmires.springeropen.com/track/pdf/10.1186/s13550-020-0603-9
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-408918
8564 8u https://doi.org/10.1186/s13550-020-0603-9

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy